B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?

por Hengeveld, P J, Kersten, M J
Publicado 2015

Lessons learnt from a process evaluation of an exercise intervention in patients treated with autologous stem cell transplantation

por Persoon, S., Chinapaw, M.J.M., Buffart, L.M., Brug, J., Kersten, M.J., Nollet, F.
Publicado 2017

Return to work experiences of patients treated with stem cell transplantation for a hematologic malignancy

por Persoon, S., Buffart, L. M., Chinapaw, M. J. M., Nollet, F., Frings-Dresen, M. H., Koning, S., Kersten, M. J., Tamminga, S. J.
Publicado 2018

Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations

por Kersten, M J, Kraan, W, Doorduijn, J, Bromberg, J, Lam, K, Kluin, P M, van der Holt, B J, Spaargaren, M, Pals, S T
Publicado 2014

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites

por Kraan, W, Horlings, H M, van Keimpema, M, Schilder-Tol, E J M, Oud, M E C M, Scheepstra, C, Kluin, P M, Kersten, M J, Spaargaren, M, Pals, S T
Publicado 2013

Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma

por de Gast, G C, Batchelor, D, Kersten, M J, Vyth-Dreese, F A, Sein, J, van de Kasteele, W F, Nooijen, W J, Nieweg, O E, Waal, M A de, Boogerd, W
Publicado 2003

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma

por Verra, N, Jansen, R, Groenewegen, G, Mallo, H, Kersten, M J, Bex, A, Vyth-Dreese, F A, Sein, J, van de Kasteele, W, Nooijen, W J, de Waal, M, Horenblas, S, de Gast, G C
Publicado 2003

P1254: RESPONSE TO DA-EPOCH-R IN PATIENTS WITH HIGH GRADE B CELL LYMPHOMA IS ASSOCIATED WITH A REDUCTION OF PD1 POSITIVE EXHAUSTED CD8 T CELLS

por de Jonge, V., Duetz, C., Bruins, W., van Werkhoven, E., Nijland, M., de Heer, K., van der Poel, M., Sandberg, Y., Klerk, C., de Jong, D., Zijlstra, J., Kersten, M. J., Mutis, T., Chamuleau, M.
Publicado 2022

PB2115: TRIAL IN PROGRESS: A RANDOMIZED PHASE II STUDY OF MB-CART2019.1 COMPARED TO STANDARD OF CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR AUTOLOGOUS ST...

por Borchmann, P., Vandenberghe, P., Urbano, A., Haioun, C., Lemonnier, F., Griškevicius, L., Maury, S., Holtkamp, S., Friedrichs, B., Zadoyan, G., Hanssens, L., Brillant, C., Bethke, U., Assenmacher, M., Bürger, I., Philippe, B., Overstijns, T., Jäger, U., Kersten, M. J.
Publicado 2022

P1462: POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIE...

por Spanjaart, A. M., Pennings, E., Mutsaers, P., van Dorp, S., Jak, M., van Doesem, J., de Boer, J., Vermaat, J., Sijs-Szabo, A., van der Poel, M., Kuipers, I., Chamuleau, M., Nijhof, I., Minnema, M., Lugtenburg, P., van Meerten, T., Kersten, M. J.
Publicado 2022

P1530: PERITRANFUSIONAL C1-INHIBITOR IN PATIENTS WITH SEVERE COMPLEMENT-MEDIATED AUTOIMMUNE HEMOLYTIC ANEMIA: AN OPEN LABEL PHASE 2 TRIAL.

por de Boer, E. C. W., Jalink, M., Delvasto-Nuñes, L., Meulenbroek, E. M., Baas, I., Janssen, S. R., Dijkman, E. E., Gelderman, K. A., Wouters, D., Engel, M. D., de Haas, M., Kersten, M.-J., Jongerius, I., Zeerleder, S., Vos, J. M.
Publicado 2022

P1105: FINAL RESULTS OF THE PHASE I/II HOVON124/ECWM-R2 STUDY INCLUDING 2-YEAR RITUXIMAB MAINTENANCE AFTER INDUCTION WITH IXAZOMIB, RITUXIMAB AND DEXAMETHASONE IN RELAPSED WALDENST...

por Dimopoulos, M.-A., Amaador, K., Minnema, M. C., Nasserinejad, K., Kap, M., Kastritis, E., Gavriatopoulou, M., Kraan, W., Chamuleau, M. E. D., Deeren, D., Tick, L., Doorduijn, J. K., Offner, F., Böhmer, L. H., Liu, R. D., Pals, S. T., Vos, J. M., Kersten, M. J.
Publicado 2022

P1209: INCIDENCE, TREATMENT AND OUTCOME OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA: A POPULATION-BASED COHORT STUDY IN THE NETHERLANDS

por Meeuwes, F. O., Brink, M., Van der Poel, M. W., Kersten, M. J., Wondergem, M. J., Mutsaers, P. G., Böhmer, L. H., Woei-A-Jin, F. J. S. H., Visser, O., Oostvogels, R., Jansen, P. M., Plattel, W. J., Huls, G. A., Vermaat, J. S., Nijland, M.
Publicado 2022

P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ZUMA-2

por Wang, M. L., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Flinn, I. W., Miklos, D. B., Pagel, J. M., Kersten, M. J., Houot, R., Beitinjaneh, A., Peng, W., Fang, X., Shen, R. R., Siddiqi, R., Kloos, I., Reagan, P. M.
Publicado 2022

Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens

por Oosten, L. E. M., Chamuleau, M. E. D., Thielen, F. W., de Wreede, L. C., Siemes, C., Doorduijn, J. K., Smeekes, O. S., Kersten, M. J., Hardi, L., Baars, J. W., Demandt, A. M. P., Stevens, W. B. C., Nijland, M., van Imhoff, G. W., Brouwer, R., Uyl-de Groot, C. A., Kluin, P. M., de Jong, D., Veelken, H.
Publicado 2017